The post Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO appeared on BitcoinEthereumNews.com. Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills. Jeff Sciortino for Forbes The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion. Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion. A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share. Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023. Medline did not immediately respond to an email seeking comment. Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who… The post Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO appeared on BitcoinEthereumNews.com. Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills. Jeff Sciortino for Forbes The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion. Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion. A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share. Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023. Medline did not immediately respond to an email seeking comment. Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who…

Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO

For feedback or concerns regarding this content, please contact us at [email protected]

Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills.

Jeff Sciortino for Forbes

The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion.

Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion.

A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share.

Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023.

Medline did not immediately respond to an email seeking comment.

Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who worked as a seamstress at a local hospital asked Mills if he could make and sell them hospital garments, the medical business was born. Over the subsequent decades, the company invented the first surgeon’s gown with 360-degree coverage, were among the first to commercialize the blue and green fabrics worn in the operating room to cut down on the lights’ glare, and were first to introduce the now ubiquitous pink-and-blue striped blankets for newborns.

Though Medline’s supplies–everything from baby blankets to bandages–are everywhere, the Mills family was largely unknown until Forbes profiled them in 2020 when Covid-19 was at its peak. At the time, its distribution of medical supplies to nursing homes, pharmacies and 45% of hospital systems nationwide was a critical part of the country’s pandemic response.

Then, in June 2021, the family–which had till then owned 100% of the company–sold a majority stake to a consortium of private-equity firms that included Blackstone Group, Carlyle Group and Hellman & Friedman, who beat out other blue-chip bidders. In October 2023, current CEO Jim Boyle took on that role, the first non-family member to hold it.

Private-equity ownership has been good for Medline. The company’s sales reached $25.5 billion in 2024, up 83% from $13.9 billion five years earlier. Meanwhile profits rebounded to $1.2 billion last year, compared with a small loss two years earlier.

MORE FROM FORBES

ForbesThis Robotic Surgery Legend Is Pouring $100 Million Into Next-Gen Medical StartupsForbesThis Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’sForbesHow A Tiny Polish Startup Became The Multi-Billion-Dollar Voice Of AIForbesHow Donald Trump Jr’s Fortune Jumped Six-Fold In A YearForbesCompanies Cut Prices For Blockbuster Weight-Loss Drugs

Source: https://www.forbes.com/sites/amyfeldman/2025/12/08/medlines-mills-founding-family-has-6-billion-plus-stake-in-its-upcoming-blockbuster-ipo/

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Loopring Price Prediction 2026, 2027 and 2030: Can LRC Be a Game-Changing Coin?

Loopring Price Prediction 2026, 2027 and 2030: Can LRC Be a Game-Changing Coin?

Loopring LRC price prediction 2026–2030: ~$0.025, Binance delisting April 1 2026, wallet shut June 2025, CEO resigned. Layer-3 pivot. Can LRC survive?
Share
Blockchainreporter2026/04/02 17:20
WTI rises above 101.00 as Trump’s Iran stance fuels supply fears

WTI rises above 101.00 as Trump’s Iran stance fuels supply fears

The post WTI rises above 101.00 as Trump’s Iran stance fuels supply fears appeared on BitcoinEthereumNews.com. West Texas Intermediate (WTI) oil price rises over
Share
BitcoinEthereumNews2026/04/02 17:07
DOGE ETF Hype Fades as Whales Sell and Traders Await Decline

DOGE ETF Hype Fades as Whales Sell and Traders Await Decline

The post DOGE ETF Hype Fades as Whales Sell and Traders Await Decline appeared on BitcoinEthereumNews.com. Leading meme coin Dogecoin (DOGE) has struggled to gain momentum despite excitement surrounding the anticipated launch of a US-listed Dogecoin ETF this week. On-chain data reveals a decline in whale participation and a general uptick in coin selloffs across exchanges, hinting at the possibility of a deeper price pullback in the coming days. Sponsored Sponsored DOGE Faces Decline as Whales Hold Back, Traders Sell The market is anticipating the launch of Rex-Osprey’s Dogecoin ETF (DOJE) tomorrow, which is expected to give traditional investors direct exposure to Dogecoin’s price movements.  However, DOGE’s price performance has remained muted ahead of the milestone, signaling a lack of enthusiasm from traders. According to on-chain analytics platform Nansen, whale accumulation has slowed notably over the past week. Large investors, with wallets containing DOGE coins worth more than $1 million, appear unconvinced by the ETF narrative and have reduced their holdings by over 4% in the past week.  For token TA and market updates: Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here. Dogecoin Whale Activity. Source: Nansen When large holders reduce their accumulation, it signals a bearish shift in market sentiment. This reduced DOGE demand from significant players can lead to decreased buying pressure, potentially resulting in price stagnation or declines in the near term. Sponsored Sponsored Furthermore, DOGE’s exchange reserve has risen steadily in the past week, suggesting that more traders are transferring DOGE to exchanges with the intent to sell. As of this writing, the altcoin’s exchange balance sits at 28 billion DOGE, climbing by 12% in the past seven days. DOGE Balance on Exchanges. Source: Glassnode A rising exchange balance indicates that holders are moving their assets to trading platforms to sell rather than to hold. This influx of coins onto exchanges increases the available supply in…
Share
BitcoinEthereumNews2025/09/18 05:07

Trade GOLD, Share 1,000,000 USDT

Trade GOLD, Share 1,000,000 USDTTrade GOLD, Share 1,000,000 USDT

0 fees, up to 1,000x leverage, deep liquidity